| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets |
0 |
0 |
0 |
0 |
1 |
2 |
2 |
5 |
| Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets |
0 |
0 |
1 |
16 |
0 |
0 |
2 |
29 |
| Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
19 |
| Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
15 |
| Assessing the population health impact of market interventions to improve access to antiretroviral treatment |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
| COVID-19 and clinical trials |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
| Competition Law, Intellectual Property, and the Pharmaceutical Sector |
0 |
0 |
0 |
0 |
0 |
1 |
6 |
36 |
| Competition and the Efficiency of Markets for Technology |
0 |
0 |
0 |
70 |
2 |
5 |
5 |
134 |
| Competition and the Efficiency of Markets for Technology |
0 |
0 |
0 |
0 |
1 |
3 |
4 |
8 |
| Competition and the Efficiency of Markets for Technology |
0 |
0 |
0 |
0 |
0 |
3 |
4 |
6 |
| Competition and the Efficiency of Markets for Technology |
0 |
0 |
0 |
94 |
4 |
5 |
5 |
140 |
| Competition law, intellectual property, and the pharmaceutical sector |
0 |
0 |
0 |
0 |
1 |
2 |
5 |
42 |
| Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did They Get Easier During the Banking Boom? Did It Matter to Bank Lending? |
0 |
0 |
0 |
189 |
2 |
2 |
5 |
822 |
| Did U.S. bank supervisors get tougher during the credit crunch? Did they get easier during the banking boom? Did it matter to bank lending? |
0 |
0 |
0 |
138 |
1 |
1 |
1 |
533 |
| Do Patents Work? Evidence from Pharmaceutical Innovation |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
16 |
| Economic Issues in Assessing Potential and Nascent Competition |
0 |
0 |
0 |
0 |
1 |
2 |
6 |
15 |
| Estimating the Benefits of Cancer Treatments |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
10 |
| Estimating the Benefits of Innovation |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
45 |
| Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
39 |
| Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act |
0 |
0 |
0 |
4 |
0 |
0 |
2 |
49 |
| Government Free-riding in Research Funding |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
| Hot tub time machine? What role for Towercast in EU merger control |
0 |
0 |
0 |
0 |
3 |
3 |
8 |
8 |
| Incentives for pharmaceutical innovation: What’s working, what’s lacking |
0 |
0 |
0 |
1 |
1 |
3 |
4 |
11 |
| Inefficiencies in technology transfer: theory and empirics |
0 |
0 |
1 |
59 |
2 |
2 |
4 |
329 |
| Inefficiencies in technology transfer: theory and empirics |
0 |
0 |
0 |
13 |
2 |
3 |
5 |
100 |
| Inefficiencies in technology transfer: theory and empirics |
0 |
0 |
0 |
0 |
1 |
2 |
4 |
4 |
| Inefficiencies in the sale of ideas: theory and empirics |
0 |
0 |
0 |
106 |
1 |
3 |
7 |
123 |
| Inefficiencies in the sale of ideas: theory and empirics |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
2 |
| Innovation pharmaceutique: comment combler le retard français ? |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
15 |
| Intellectual Property Rights and Access to Innovation: Evidence from TRIPS |
0 |
0 |
1 |
61 |
6 |
10 |
23 |
213 |
| Intellectual Property Rights and Access to Innovation: Evidence from TRIPS |
0 |
0 |
0 |
0 |
1 |
2 |
2 |
9 |
| Intellectual property rights and access to innovation: evidence from TRIPS |
0 |
0 |
0 |
0 |
1 |
2 |
7 |
41 |
| Intersection of Intellectual Property and Competition Policy in Recent Cases |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
9 |
| Investments in Pharmaceuticals Before and After TRIPS |
0 |
0 |
0 |
88 |
4 |
5 |
7 |
268 |
| Investments in Pharmaceuticals Before and After TRIPS |
0 |
0 |
1 |
41 |
1 |
3 |
7 |
161 |
| Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
16 |
| Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs |
0 |
0 |
0 |
45 |
0 |
2 |
4 |
61 |
| Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
55 |
| Korean pharmaceutical industry policy: lessons for Korea |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
6 |
| Productivity and competitiveness in the euro area: A view from France |
0 |
0 |
0 |
0 |
0 |
1 |
5 |
73 |
| Productivity and competitiveness in the euro area: A view from France |
0 |
0 |
0 |
0 |
1 |
4 |
7 |
15 |
| Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research |
0 |
0 |
1 |
125 |
0 |
2 |
7 |
369 |
| Strategic Interaction Among Governments in the Provision of a Global Public Good |
0 |
0 |
0 |
30 |
1 |
1 |
1 |
69 |
| Strategic Responses to Parallel Trade |
0 |
0 |
0 |
131 |
0 |
0 |
1 |
393 |
| Strategic interaction among governments in the provision of a global public good |
0 |
0 |
0 |
0 |
1 |
1 |
4 |
21 |
| Strategic interaction among governments in the provision of a global public good |
0 |
0 |
0 |
0 |
2 |
3 |
3 |
13 |
| Study for European Commission (DG Internal Market, Industry, Entrepreneurship and SMEs) on supplementary patent certificates |
0 |
0 |
0 |
0 |
1 |
1 |
6 |
133 |
| The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
4 |
| The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals |
0 |
0 |
0 |
0 |
2 |
4 |
5 |
6 |
| The Effects of Pharmaceutical Innovation on Cancer Mortality |
0 |
1 |
1 |
11 |
2 |
6 |
9 |
52 |
| The Effects of Pharmaceutical Innovation on Cancer Mortality Rates |
0 |
1 |
2 |
99 |
2 |
6 |
10 |
208 |
| The More We Die, The More We Sell? A Simple Test of the Home-Market Effect |
0 |
0 |
0 |
0 |
0 |
3 |
4 |
63 |
| The More We Die, The More We Sell? A Simple Test of the Home-Market Effect |
0 |
0 |
0 |
23 |
1 |
3 |
5 |
92 |
| The More We Die, The More We Sell? A Simple Test of the Home-Market Effect* |
0 |
0 |
0 |
0 |
4 |
5 |
7 |
11 |
| The Single Market in Pharmaceuticals |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
14 |
| The economics of new product launches and access to pharmaceutical products in the EU: A perspective on the EC’s proposed reform of the EU pharmaceutical legislation |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
10 |
| Total Working Papers |
0 |
2 |
8 |
1,348 |
56 |
114 |
225 |
4,960 |
LogEc is hosted by the
Örebro University School of Business.